{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:05:54Z","timestamp":1790283954871,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75A50121C00077"],"award-info":[{"award-number":["75A50121C00077"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanmic.2026.101492","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:09:49Z","timestamp":1790161789000},"page":"101492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and immunogenicity of a recombinant vesicular stomatitis virus-based Sudan virus vaccine in adults in the USA: a single-blind, first-in-human, dose-escalation phase 1 clinical trial"],"prefix":"10.1016","author":[{"given":"Dagna S","family":"Laufer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3416-7362","authenticated-orcid":false,"given":"Arianna","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Philiponis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia E","family":"Fast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-6049","authenticated-orcid":false,"given":"Marija","family":"Zaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Sigei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel V","family":"Bromell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-079X","authenticated-orcid":false,"given":"Natalia","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0435-7253","authenticated-orcid":false,"given":"Heejin","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhani","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Pindolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimah","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Boutwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Meller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Talasila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Sayeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja","family":"Chandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie F","family":"Mabushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S","family":"Denham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-0142","authenticated-orcid":false,"given":"Andrew","family":"Kilianski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Malkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati B","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101492_bib1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMsr1513109","article-title":"After Ebola in West Africa--unpredictable risks, preventable epidemics","volume":"375","author":"Agua-Agum","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101492_bib2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101492_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101492_bib4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1473-3099(24)00419-5","article-title":"Effectiveness of rVSV-ZEBOV vaccination during the 2018\u201320 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study","volume":"24","author":"Meakin","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101492_bib5","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2666-5247(23)00001-0","article-title":"Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques","volume":"4","author":"Marzi","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101492_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(77)92001-3","article-title":"Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent","volume":"1","author":"Bowen","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101492_bib7","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.15585\/mmwr.mm7145a5","article-title":"Notes from the field: outbreak of Ebola virus disease caused by Sudan Ebolavirus - Uganda, August\u2013October 2022","volume":"71","author":"Kiggundu","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanmic.2026.101492_bib9","doi-asserted-by":"crossref","first-page":"e1684","DOI":"10.1016\/S2214-109X(24)00260-2","article-title":"Ebola disease outbreak caused by the Sudan virus in Uganda, 2022: a descriptive epidemiological study","volume":"12","author":"Kabami","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101492_bib10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","article-title":"Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial","volume":"23","author":"Mwesigwa","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101492_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101022","article-title":"Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial","volume":"6","author":"Jenkin","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101492_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.vaccine.2023.12.053","article-title":"Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection","volume":"42","author":"To","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101492_bib13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"Kibuuka","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101492_bib14","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/JVI.00456-08","article-title":"Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates","volume":"82","author":"Geisbert","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.lanmic.2026.101492_bib15","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.lanmic.2026.101492_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/vaccines9030190","article-title":"Development of pandemic vaccines: ERVEBO case study","volume":"9","author":"Wolf","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanmic.2026.101492_bib17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101492_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101244","article-title":"Fast-acting single-dose vesicular stomatitis virus-Sudan virus vaccine: a challenge study in macaques","volume":"6","author":"Fletcher","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2026.101492_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41579-019-0187-4","article-title":"New filovirus disease classification and nomenclature","volume":"17","author":"Kuhn","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lanmic.2026.101492_bib20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/vaccines10081211","article-title":"Assays for the evaluation of the immune response to Marburg and Ebola Sudan vaccination-filovirus animal nonclinical group anti-Marburg virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay and a pseudovirion neutralization assay","volume":"10","author":"Rudge","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanmic.2026.101492_bib21","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa2501073","article-title":"Safety and immunogenicity of an rVSV Lassa fever vaccine candidate","volume":"393","author":"Malkin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101492_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/vaccines14070592","article-title":"Development and qualification of a VSV-N IgG ELISA to assess vector-directed humoral immunity in VSV-vectored vaccine studies","volume":"14","author":"Ayorinde","year":"2026","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanmic.2026.101492_bib23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3390\/vaccines10101582","article-title":"Nonhuman primates are protected against Marburg virus disease by vaccination with a vesicular stomatitis virus vector-based vaccine prepared under conditions to allow advancement to human clinical trials","volume":"10","author":"Cooper","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.lanmic.2026.101492_bib24","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1128\/JVI.05991-11","article-title":"The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate","volume":"86","author":"Cobleigh","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.lanmic.2026.101492_bib25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.lanmic.2026.101492_bib26","article-title":"Recent updates on correlates of vaccine-induced protection","volume":"13","author":"Plotkin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanmic.2026.101492_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.lanmic.2026.101492_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire glycoprotein: standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.lanmic.2026.101492_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001567","article-title":"Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates","volume":"6","author":"Mire","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.lanmic.2026.101492_bib30","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.cmi.2023.08.026","article-title":"Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability","volume":"29","author":"Huttner","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2026.101492_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1109486","article-title":"Approaches to demonstrating the effectiveness of filovirus vaccines: lessons from Ebola and COVID-19","volume":"14","author":"Gruber","year":"2023","journal-title":"Front Immunol"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726001473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524726001473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:54:22Z","timestamp":1790283262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524726001473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2666524726001473"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101492","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a recombinant vesicular stomatitis virus-based Sudan virus vaccine in adults in the USA: a single-blind, first-in-human, dose-escalation phase 1 clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101492"}}